Rosch-Uchida
Payments companies reported to CMS as associated with Rosch-Uchida. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rosch-Uchida, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rosch-Uchida
These are the largest totals companies reported as associated with Rosch-Uchida. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Kei Yamada | Atlanta, GA | Vascular & Interventional Radiology | $29,594.75 |
| Mark Lessne | Charlotte, NC | Diagnostic Radiology | $26,390.50 |
| Christopher Molvar | Chicago, IL | Vascular & Interventional Radiology | $18,595.57 |
| Bulent Arslan | Chicago, IL | Vascular & Interventional Radiology | $16,278.79 |
| Merve Ozen | Scottsdale, AZ | Vascular & Interventional Radiology | $13,013.51 |
| Hector Ferral | Evanston, IL | Vascular & Interventional Radiology | $9,455.00 |
| Riad Salem | Chicago, IL | Vascular & Interventional Radiology | $6,995.18 |
| Siobhan Flanagan | Minneapolis, MN | Vascular & Interventional Radiology | $1,960.00 |
| Muhammad Jaffari | Middletown, NY | General Practice | $1,953.21 |
| Thomas Leventhal | Minneapolis, MN | Gastroenterology (Internal Medicine) | $1,880.00 |
Prescribed Rosch-Uchida?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.